Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 160.7 SEK 0.63% Market Closed
Market Cap: 12.9B SEK
Have any thoughts about
Biotage AB?
Write Note

Biotage AB
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotage AB
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Biotage AB
STO:BIOT
Long-Term Investments
kr25m
CAGR 3-Years
28%
CAGR 5-Years
8%
CAGR 10-Years
28%
AddLife AB
STO:ALIF B
Long-Term Investments
kr9m
CAGR 3-Years
1%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Long-Term Investments
kr45.5m
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Long-Term Investments
kr90k
CAGR 3-Years
-75%
CAGR 5-Years
-45%
CAGR 10-Years
-31%
MedCap AB (publ)
STO:MCAP
Long-Term Investments
kr500k
CAGR 3-Years
-44%
CAGR 5-Years
-22%
CAGR 10-Years
-9%
M
Magle Chemoswed Holding AB
STO:MAGLE
Long-Term Investments
kr55k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biotage AB
Glance View

Market Cap
12.9B SEK
Industry
Life Sciences Tools & Services

Biotage AB, a Swedish life sciences company, has carved a significant niche within the analytical and organic chemistry sectors since its inception. The company's core operations revolve around the development of innovative solutions designed to facilitate drug discovery, genetic research, and infection diagnostics. By offering products that simplify and accelerate chemical synthesis, Biotage has become essential to the pharmaceutical and biotechnology industries. The company's product lineup includes automated sample preparation systems, flash chromatography instruments, and peptide synthesis solutions. These tools are indispensable for researchers and lab technicians, making complex laboratory processes more efficient and less time-consuming. Financially, Biotage generates revenue through the sale and distribution of its cutting-edge laboratory instruments and their accompanying consumables. In addition to equipment sales, the company also engages in service contracts and after-sales support, which provides a steady stream of recurring income. This dual model of one-time equipment purchases combined with ongoing service and supply needs ensures a stable revenue base. Biotage stays competitive by continually innovating and refining its technology, ensuring its solutions remain indispensable to scientists addressing critical challenges in medicine, environmental testing, and other fields that demand highly precise chemical processes.

BIOT Intrinsic Value
181.41 SEK
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Biotage AB's Long-Term Investments?
Long-Term Investments
25m SEK

Based on the financial report for Sep 30, 2024, Biotage AB's Long-Term Investments amounts to 25m SEK.

What is Biotage AB's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
28%

Over the last year, the Long-Term Investments growth was 32%. The average annual Long-Term Investments growth rates for Biotage AB have been 28% over the past three years , 8% over the past five years , and 28% over the past ten years .

Back to Top